# Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.

> **NCT01715233** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 27 (actual)

## Conditions studied

- Metastatic Esophageal Cancer
- Gastroesophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Leucovorin
- **DRUG:** Fluorouracil
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01715233
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-06
- **Final completion:** 2017-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01715233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01715233, "Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01715233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*